Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
RENESE-R vs ALDORIL D30
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Thiazide diuretic; inhibits sodium-chloride symporter in distal convoluted tubule, reducing sodium and water reabsorption.
Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.
Edema due to congestive heart failure,Mild to moderate hypertension
Hypertension
Initial: 5 mg orally once daily, increased as needed to 10 mg once daily; maximum 10 mg/day.
Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.
Terminal elimination half-life: 13-16 hours; clinical context: supports once-daily dosing
Terminal elimination half-life of hydrochlorothiazide is 6-15 hours; methyldopa half-life is 1.8 hours (normal renal function). In renal impairment, half-life of both components is prolonged.
Metabolized by liver (CYP450) to active metabolite; excreted in feces (65%) and urine (35%).
Methyldopa is metabolized by conjugation (catechol-O-methyltransferase) and hepatic sulfation; hydrochlorothiazide is not extensively metabolized and is excreted unchanged by the kidney.
Renal: 50% unchanged; fecal: 0%; biliary: 0%
Renal: approximately 50% as parent drug and metabolites; biliary/fecal: minimal, less than 5%.
80-90% bound to plasma proteins, primarily albumin
Methyldopa: <10% bound to plasma proteins; hydrochlorothiazide: 40-68% bound to albumin.
0.2-0.3 L/kg; indicates distribution mainly in extracellular fluid
Methyldopa: Vd 0.2-0.3 L/kg (distributes into tissues, crosses placenta); hydrochlorothiazide: Vd 0.75-1.5 L/kg (extensively distributed, does not cross blood-brain barrier significantly).
Oral: 70-80%
Oral bioavailability of methyldopa is approximately 25% (variable, influenced by gut metabolism); hydrochlorothiazide bioavailability is 65-75%.
GFR 30-50 m L/min: reduce dose by 50%; GFR <30 m L/min: not recommended.
GFR 30-60 m L/min: reduce dose by 50%; GFR <30 m L/min: not recommended.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: avoid use.
Child-Pugh Class B or C: contraindicated; use not recommended.
Not approved for use in pediatric patients; safety and efficacy not established.
Not recommended for use in pediatric patients due to lack of safety and efficacy data.
Initiate at 2.5 mg orally once daily; use caution due to increased sensitivity to electrolyte disturbances and hypotension.
Start with lowest dose; monitor for hypotension, electrolyte imbalance, and CNS effects; consider reduced initial dose.
No FDA boxed warning.
None
May cause hypokalemia and hypomagnesemia,Can precipitate hyperuricemia and gout,May increase serum calcium,Use with caution in diabetes (may increase blood glucose),Photosensitivity reactions reported,Sulfonamide allergy: possible cross-reactivity
May cause hemolytic anemia, liver disorders, positive Coombs test, sedation, depression, and hypersensitivity reactions. Hydrochlorothiazide may cause electrolyte imbalance, hyperuricemia, photosensitivity, and exacerbation of systemic lupus erythematosus. Use with caution in renal impairment, hepatic disease, and in patients with a history of drug-induced hemolytic anemia.
Anuria,Hypersensitivity to sulfonamides or thiazides,Severe renal impairment (creatinine clearance <30 m L/min),Hepatic coma or pre-coma
Active hepatic disease, history of previous methyldopa therapy-associated liver disorders; anuria; hypersensitivity to methyldopa, hydrochlorothiazide, or sulfonamide-derived drugs.
Avoid excessive salt intake as it can reduce the antihypertensive effect. Limit alcohol consumption, which may enhance orthostatic hypotension. High-potassium foods (e.g., bananas, oranges, spinach) are generally safe but monitor potassium levels as thiazides can cause hypokalemia; supplement potassium if indicated. Grapefruit juice has no known interaction with this combination.
Food may decrease absorption of methyldopa. Avoid excessive intake of high-potassium foods (e.g., bananas, oranges) unless directed. Hydrochlorothiazide may cause potassium depletion; maintain adequate dietary potassium. Avoid natural licorice as it can worsen hypokalemia.
Renese-R (polythiazide) is a thiazide diuretic. Use in pregnancy, especially during the first and second trimesters, is associated with an increased risk of fetal or neonatal jaundice, thrombocytopenia, and possible other adverse reactions that have occurred in adults. Because thiazides cross the placental barrier and appear in cord blood, use during the third trimester may cause electrolyte disturbances, hypoglycemia, and other effects. The drug should be used only if clearly needed and if the potential benefit justifies the potential risk to the fetus.
First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; possible fetal bradycardia and neonatal hypotension. Hydrochlorothiazide may cause fetal/neonatal jaundice, thrombocytopenia, and electrolyte disturbances.
Thiazides are excreted in human milk in small amounts. There is no published M/P ratio for polythiazide specifically; however, based on thiazide class, the M/P ratio is approximately 0.1-0.5. Breastfeeding is generally discouraged due to potential for adverse effects in the infant, including electrolyte imbalance and thrombocytopenia. Alternative agents are preferred, especially in high-dose therapy or when monitoring is not feasible.
Methyldopa is excreted in breast milk in low concentrations; M/P ratio approximately 0.2. Hydrochlorothiazide is excreted in minimal amounts; may suppress lactation. Consider risks versus benefits.
Pregnancy may alter pharmacokinetics of thiazides due to increased plasma volume and renal blood flow. Dose adjustments are not well established; however, polythiazide should be used at the lowest effective dose to avoid excessive diuresis and electrolyte imbalances. If used, monitor maternal electrolytes and renal function closely. The dose may need to be reduced if signs of hypovolemia or electrolyte abnormalities develop. Postpartum, consider dose readjustment as plasma volume normalizes.
Methyldopa: Pregnancy-induced plasma volume expansion may require dose titration; monitor blood pressure and adjust accordingly. Hydrochlorothiazide: Often avoided in pregnancy due to volume depletion risks; if used, monitor electrolytes and renal function, no pharmacokinetic data necessitate routine dose adjustment.
Renese-R is a fixed-dose combination of polythiazide, a thiazide diuretic, and reserpine, a Rauwolfia alkaloid antihypertensive. Watch for hypokalemia, especially in patients on digoxin. Reserpine can cause significant bradycardia and depression; avoid in patients with history of depression. Discontinue at least 2 weeks before electroconvulsive therapy. Monitor for orthostatic hypotension, especially when used with other antihypertensives.
ALDORIL D30 combines methyldopa (central alpha-2 agonist) and hydrochlorothiazide (thiazide diuretic). Monitor for orthostatic hypotension, especially at initiation. Taper not needed for methyldopa but discontinue if fever or liver dysfunction occurs. Interferes with urinary catecholamine measurements (false elevation). Hydrochlorothiazide may cause hyponatremia, hypokalemia, and hyperglycemia; check electrolytes and glucose periodically.
Take this medication exactly as prescribed, usually once daily in the morning to avoid nighttime urination.,Avoid alcohol and standing up quickly from lying or sitting positions to prevent dizziness.,Report symptoms of depression, severe drowsiness, or slow heartbeat to your doctor immediately.,You may need to have regular blood tests to monitor potassium levels and kidney function.,This medication can cause increased sensitivity to sunlight; use sunscreen and protective clothing.,Do not stop taking this drug abruptly without consulting your doctor.
Take exactly as prescribed, preferably with food to reduce stomach upset.,Rise slowly from sitting or lying down to prevent dizziness.,This drug may make you drowsy; avoid driving or operating machinery until you know how it affects you.,Report fever, unexplained fatigue, jaundice, or dark urine immediately.,Weigh yourself daily and report rapid weight gain or swelling.,Limit alcohol intake as it can increase side effects.,Do not use salt substitutes containing potassium without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about RENESE-R vs ALDORIL D30, answered by our medical review team.
RENESE-R is a Antihypertensive Combination that works by Thiazide diuretic; inhibits sodium-chloride symporter in distal convoluted tubule, reducing sodium and water reabsorption.. ALDORIL D30 is a Antihypertensive Combination that works by Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between RENESE-R and ALDORIL D30 depend on the specific clinical indication. These are both Antihypertensive Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of RENESE-R is: Initial: 5 mg orally once daily, increased as needed to 10 mg once daily; maximum 10 mg/day.. The standard adult dose of ALDORIL D30 is: Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between RENESE-R and ALDORIL D30 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. RENESE-R is classified as Category C. Renese-R (polythiazide) is a thiazide diuretic. Use in pregnancy, especially during the first and second trimesters, is associated with an increased risk of fetal or neonatal jaund. ALDORIL D30 is classified as Category C. First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; p. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.